Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
288 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Pulmonary Fibrosis - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Pulmonary Fibrosis - Pipeline Review, H1 2015', provides an overview of the Pulmonary Fibrosis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Fibrosis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Pulmonary Fibrosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Pulmonary Fibrosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Pulmonary Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Pulmonary Fibrosis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Pulmonary Fibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Pulmonary Fibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Pulmonary Fibrosis Overview 10 Therapeutics Development 11 Pipeline Products for Pulmonary Fibrosis - Overview 11 Pipeline Products for Pulmonary Fibrosis - Comparative Analysis 12 Pulmonary Fibrosis - Therapeutics under Development by Companies 13 Pulmonary Fibrosis - Therapeutics under Investigation by Universities/Institutes 19 Pulmonary Fibrosis - Pipeline Products Glance 20 Late Stage Products 20 Clinical Stage Products 21 Early Stage Products 22 Unknown Stage Products 23 Pulmonary Fibrosis - Products under Development by Companies 24 Pulmonary Fibrosis - Products under Investigation by Universities/Institutes 30 Pulmonary Fibrosis - Companies Involved in Therapeutics Development 31 AdAlta Pty Ltd. 31 Aeolus Pharmaceuticals, Inc. 32 AnaptysBio, Inc. 33 Angion Biomedica Corp. 34 Aquinox Pharmaceuticals Inc. 35 Auspex Pharmaceuticals, Inc. 36 Biogen Idec Inc. 37 BiOrion Technologies B.V. 38 Boehringer Ingelheim GmbH 39 Bristol-Myers Squibb Company 40 Carolus Therapeutics, Inc. 41 Celgene Corporation 42 Chong Kun Dang Pharmaceutical Corp. 43 Compugen Ltd. 44 Corridor Pharmaceuticals Inc. 45 Digna Biotech, S.L. 46 Eli Lilly and Company 47 F. Hoffmann-La Roche Ltd. 48 FibroGen, Inc. 49 Five Prime Therapeutics, Inc. 50 Galectin Therapeutics, Inc. 51 GenKyoTex S.A. 52 Gilead Sciences, Inc. 53 GlaxoSmithKline plc 54 HanAll Biopharma Co., Ltd. 55 Histocell S.L. 56 iBio, Inc. 57 IMMD Inc. 58 ImmuneWorks, LLC 59 IntelGenx Corp. 60 InterMune, Inc. 61 Inventiva SAS 62 Kasiak Research Pvt. Ltd. 63 Kyorin Pharmaceutical Co., Ltd. 64 Lanthio Pharma B.V. 65 Lpath, Inc. 66 LTT Bio-Pharma Co., Ltd. 67 MedImmune, LLC 68 Mesoblast Limited 69 miRagen Therapeutics, Inc. 70 Moerae Matrix, Inc. 71 MSM Protein Technologies, Inc. 72 NicOx S.A. 73 Pacific Therapeutics Ltd. 74 Pharmaxis Limited 75 Pluristem Therapeutics Inc. 76 Progenra, Inc. 77 Promedior, Inc. 78 ProMetic Life Sciences Inc. 79 Pulmatrix, Inc. 80 RestorGenex Corporation 81 Rhizen Pharmaceuticals SA 82 Sanofi 83 Therametrics holding AG 84 Vectura Group plc 85 Pulmonary Fibrosis - Therapeutics Assessment 86 Assessment by Monotherapy Products 86 Assessment by Combination Products 87 Assessment by Target 88 Assessment by Mechanism of Action 92 Assessment by Route of Administration 95 Assessment by Molecule Type 97 Drug Profiles 99 (pentoxifylline + acetylcysteine) - Drug Profile 99 ABC-294640 - Drug Profile 100 AEOL-10150 - Drug Profile 102 AM-0010 - Drug Profile 105 ANG-3070 - Drug Profile 106 ANG-3298 - Drug Profile 107 Antibodies to Inhibit LPA1 for Idiopathic Pulmonary Fibrosis - Drug Profile 108 AQX-1125 - Drug Profile 109 BB-3 - Drug Profile 111 BMS-986020 - Drug Profile 113 BOT-191 - Drug Profile 114 C-301 - Drug Profile 115 CC-539 - Drug Profile 116 CC-90001 - Drug Profile 117 CG-1011 - Drug Profile 118 CGEN-25009 - Drug Profile 119 CKD-942 - Drug Profile 120 CT-140 - Drug Profile 121 CT-2009 - Drug Profile 122 DB-02901 - Drug Profile 123 disitertide - Drug Profile 124 Drug for Idiopathic Pulmonary Fibrosis - Drug Profile 126 Drugs to Antagonize IGF-1 Receptor for Acute Lung Injury and Pulmonary Fibrosis - Drug Profile 127 FG-3019 - Drug Profile 128 FPA-008 - Drug Profile 130 GKT-137831 - Drug Profile 131 GR-MD-02 - Drug Profile 132 HC-016 - Drug Profile 134 HL-156FIB - Drug Profile 135 HR-017 - Drug Profile 136 IBIOCFB-03 - Drug Profile 137 ICG-001 - Drug Profile 138 IMD-1041 - Drug Profile 139 INT-0024 - Drug Profile 140 interferon gamma-1b - Drug Profile 141 ITMN-10534 - Drug Profile 142 ITMN-14440 - Drug Profile 143 ITMN-30162 - Drug Profile 144 IVA-337 - Drug Profile 145 IW-001 - Drug Profile 146 KBP-7018 - Drug Profile 147 lebrikizumab - Drug Profile 148 LP2 - Drug Profile 150 Lpathomab - Drug Profile 151 LT-0011 - Drug Profile 152 LY-2109761 - Drug Profile 153 MGN-4220 - Drug Profile 154 MMI-0100 - Drug Profile 155 Monoclonal Antibody for Idiopathic Pulmonary Fibrosis - Drug Profile 156 MSM-735 - Drug Profile 157 MSX-122 - Drug Profile 158 NAS-911 - Drug Profile 160 NCX-466 - Drug Profile 161 nintedanib - Drug Profile 162 Oligonucleotides for Respiratory and Oncology - Drug Profile 166 omipalisib - Drug Profile 167 P-007 - Drug Profile 168 P-17 - Drug Profile 169 P-529 - Drug Profile 171 PBF-1250 - Drug Profile 173 PBI-4050 - Drug Profile 174 phytate sodium - Drug Profile 175 pirfenidone - Drug Profile 176 PRI-724 - Drug Profile 177 PRM-151 - Drug Profile 179 PUR-1500 - Drug Profile 181 PXS-25 - Drug Profile 182 PXS-4820 - Drug Profile 183 PXS-5033-A - Drug Profile 184 PXS-64 - Drug Profile 185 Recombinant Human Follistatin - Drug Profile 186 Refacell-IPF - Drug Profile 187 RNAi Oligonucleotides for Idiopathic Pulmonary Fibrosis - Drug Profile 188 RP-6503 - Drug Profile 189 SAR-156597 - Drug Profile 190 SD-560 - Drug Profile 191 simtuzumab - Drug Profile 192 Small Molecule 1 for Chronic Respiratory Diseases - Drug Profile 194 Small Molecule 2 for Chronic Respiratory Diseases - Drug Profile 195 Small Molecule to Antagonize Integrin Alpha V for Idiopathic Pulmonary Fibrosis - Drug Profile 196 Small Molecule to Inhibit NOX 1 and 4 - Drug Profile 197 Small Molecules to Antagonize LPA1 Receptor for Pulmonary Fibrosis - Drug Profile 198 Small Molecules to Inhibit LOXL2 for Oncology and Fibrosis - Drug Profile 199 Small Molecules to Inhibit USP34 for Idiopathic Pulmonary Fibrosis - Drug Profile 200 SPL-334 - Drug Profile 201 Stem Cell Therapy for Asthma and Pulmonary Fibrosis - Drug Profile 202 Stem Cell Therapy for Idiopathic Lung Fibrosis - Drug Profile 203 Stem Cell Therapy for Pulmonary Fibrosis - Drug Profile 204 STX-100 - Drug Profile 205 Synthetic Peptides to Antagonize TGF-Beta Receptor for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology - Drug Profile 206 Synthetic Peptides to Inhibit PDE-4A4 for Pulmonary Fibrosis and Nerve Injury - Drug Profile 208 TD-139 - Drug Profile 209 tipelukast - Drug Profile 210 tralokinumab - Drug Profile 212 vismodegib - Drug Profile 214 Pulmonary Fibrosis - Recent Pipeline Updates 217 Pulmonary Fibrosis - Dormant Projects 265 Pulmonary Fibrosis - Discontinued Products 269 Pulmonary Fibrosis - Product Development Milestones 270 Featured News & Press Releases 270 Appendix 280 Methodology 280 Coverage 280 Secondary Research 280 Primary Research 280 Expert Panel Validation 280 Contact Us 281 Disclaimer 281
List of Tables Number of Products under Development for Pulmonary Fibrosis, H1 2015 18 Number of Products under Development for Pulmonary Fibrosis - Comparative Analysis, H1 2015 19 Number of Products under Development by Companies, H1 2015 21 Number of Products under Development by Companies, H1 2015 (Contd..1) 22 Number of Products under Development by Companies, H1 2015 (Contd..2) 23 Number of Products under Development by Companies, H1 2015 (Contd..3) 24 Number of Products under Development by Companies, H1 2015 (Contd..4) 25 Number of Products under Investigation by Universities/Institutes, H1 2015 26 Comparative Analysis by Late Stage Development, H1 2015 27 Comparative Analysis by Clinical Stage Development, H1 2015 28 Comparative Analysis by Early Stage Development, H1 2015 29 Comparative Analysis by Unknown Stage Development, H1 2015 30 Products under Development by Companies, H1 2015 31 Products under Development by Companies, H1 2015 (Contd..1) 32 Products under Development by Companies, H1 2015 (Contd..2) 33 Products under Development by Companies, H1 2015 (Contd..3) 34 Products under Development by Companies, H1 2015 (Contd..4) 35 Products under Development by Companies, H1 2015 (Contd..5) 36 Products under Investigation by Universities/Institutes, H1 2015 37 Pulmonary Fibrosis - Pipeline by AdAlta Pty Ltd., H1 2015 38 Pulmonary Fibrosis - Pipeline by Aeolus Pharmaceuticals, Inc., H1 2015 39 Pulmonary Fibrosis - Pipeline by AnaptysBio, Inc., H1 2015 40 Pulmonary Fibrosis - Pipeline by Angion Biomedica Corp., H1 2015 41 Pulmonary Fibrosis - Pipeline by Aquinox Pharmaceuticals Inc., H1 2015 42 Pulmonary Fibrosis - Pipeline by Auspex Pharmaceuticals, Inc., H1 2015 43 Pulmonary Fibrosis - Pipeline by Biogen Idec Inc., H1 2015 44 Pulmonary Fibrosis - Pipeline by BiOrion Technologies B.V., H1 2015 45 Pulmonary Fibrosis - Pipeline by Boehringer Ingelheim GmbH, H1 2015 46 Pulmonary Fibrosis - Pipeline by Bristol-Myers Squibb Company, H1 2015 47 Pulmonary Fibrosis - Pipeline by Carolus Therapeutics, Inc., H1 2015 48 Pulmonary Fibrosis - Pipeline by Celgene Corporation, H1 2015 49 Pulmonary Fibrosis - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2015 50 Pulmonary Fibrosis - Pipeline by Compugen Ltd., H1 2015 51 Pulmonary Fibrosis - Pipeline by Corridor Pharmaceuticals Inc., H1 2015 52 Pulmonary Fibrosis - Pipeline by Digna Biotech, S.L., H1 2015 53 Pulmonary Fibrosis - Pipeline by Eli Lilly and Company, H1 2015 54 Pulmonary Fibrosis - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 55 Pulmonary Fibrosis - Pipeline by FibroGen, Inc., H1 2015 56 Pulmonary Fibrosis - Pipeline by Five Prime Therapeutics, Inc., H1 2015 57 Pulmonary Fibrosis - Pipeline by Galectin Therapeutics, Inc., H1 2015 58 Pulmonary Fibrosis - Pipeline by GenKyoTex S.A., H1 2015 59 Pulmonary Fibrosis - Pipeline by Gilead Sciences, Inc., H1 2015 60 Pulmonary Fibrosis - Pipeline by GlaxoSmithKline plc, H1 2015 61 Pulmonary Fibrosis - Pipeline by HanAll Biopharma Co., Ltd., H1 2015 62 Pulmonary Fibrosis - Pipeline by Histocell S.L., H1 2015 63 Pulmonary Fibrosis - Pipeline by iBio, Inc., H1 2015 64 Pulmonary Fibrosis - Pipeline by IMMD Inc., H1 2015 65 Pulmonary Fibrosis - Pipeline by ImmuneWorks, LLC, H1 2015 66 Pulmonary Fibrosis - Pipeline by IntelGenx Corp., H1 2015 67 Pulmonary Fibrosis - Pipeline by InterMune, Inc., H1 2015 68 Pulmonary Fibrosis - Pipeline by Inventiva SAS, H1 2015 69 Pulmonary Fibrosis - Pipeline by Kasiak Research Pvt. Ltd., H1 2015 70 Pulmonary Fibrosis - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2015 71 Pulmonary Fibrosis - Pipeline by Lanthio Pharma B.V., H1 2015 72 Pulmonary Fibrosis - Pipeline by Lpath, Inc., H1 2015 73 Pulmonary Fibrosis - Pipeline by LTT Bio-Pharma Co., Ltd., H1 2015 74 Pulmonary Fibrosis - Pipeline by MedImmune, LLC, H1 2015 75 Pulmonary Fibrosis - Pipeline by Mesoblast Limited, H1 2015 76 Pulmonary Fibrosis - Pipeline by miRagen Therapeutics, Inc., H1 2015 77 Pulmonary Fibrosis - Pipeline by Moerae Matrix, Inc., H1 2015 78 Pulmonary Fibrosis - Pipeline by MSM Protein Technologies, Inc., H1 2015 79 Pulmonary Fibrosis - Pipeline by NicOx S.A., H1 2015 80 Pulmonary Fibrosis - Pipeline by Pacific Therapeutics Ltd., H1 2015 81 Pulmonary Fibrosis - Pipeline by Pharmaxis Limited, H1 2015 82 Pulmonary Fibrosis - Pipeline by Pluristem Therapeutics Inc., H1 2015 83 Pulmonary Fibrosis - Pipeline by Progenra, Inc., H1 2015 84 Pulmonary Fibrosis - Pipeline by Promedior, Inc., H1 2015 85 Pulmonary Fibrosis - Pipeline by ProMetic Life Sciences Inc., H1 2015 86 Pulmonary Fibrosis - Pipeline by Pulmatrix, Inc., H1 2015 87 Pulmonary Fibrosis - Pipeline by RestorGenex Corporation, H1 2015 88 Pulmonary Fibrosis - Pipeline by Rhizen Pharmaceuticals SA, H1 2015 89 Pulmonary Fibrosis - Pipeline by Sanofi, H1 2015 90 Pulmonary Fibrosis - Pipeline by Therametrics holding AG, H1 2015 91 Pulmonary Fibrosis - Pipeline by Vectura Group plc, H1 2015 92 Assessment by Monotherapy Products, H1 2015 93 Assessment by Combination Products, H1 2015 94 Number of Products by Stage and Target, H1 2015 96 Number of Products by Stage and Mechanism of Action, H1 2015 100 Number of Products by Stage and Route of Administration, H1 2015 103 Number of Products by Stage and Molecule Type, H1 2015 105 Pulmonary Fibrosis Therapeutics - Recent Pipeline Updates, H1 2015 224 Pulmonary Fibrosis - Dormant Projects, H1 2015 272 Pulmonary Fibrosis - Dormant Projects (Contd..1), H1 2015 273 Pulmonary Fibrosis - Dormant Projects (Contd..2), H1 2015 274 Pulmonary Fibrosis - Dormant Projects (Contd..3), H1 2015 275 Pulmonary Fibrosis - Discontinued Products, H1 2015 276
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
